Health-Related Quality of Life and Treatment Satisfaction of Patients with Malignant IDH Wild-Type Gliomas and Their Caregivers
, Markus J. Riemenschneider 8, Nils Ole Schmidt 3, Monika Klinkhammer-Schalke 2, Ralf Linker 1, Peter Hau 1 and Elisabeth Bumes 1,*
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis is a cross sectionnal study from a single german primary brain cancer center evaluating health-related quality of life and treatment satisfaction of patients with grade III and IV IDH wild-type gliomas and their primary caregiver.
The study is unique and very relevant to clinical Neuro-oncology.
The introduction and methodology are appropriate. The cross sectionnal design is not perfect to evaluate these factors but the authors are describing the study limitations appropriately.
In the introduction, the authors should clarify the sentence on page 2 lines 70-71 because its seems redundant: (patients functional status was better with a higher KPS...)
The results are well presented although the text is sometimes difficult to follow regarding what is significant and not and repetition of variables (example: page 7 lines 280-283)
The discussion and conclusion are also appropriate.
Author Response
Please see the attachment.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsThank you for this research. People living with a malignant glioma face so many challenges so any research that throws light on these issues is welcome. I think too that measuring outcomes for patients is very complex and this study goes some way to highlighting these.
I have four points to make. Please bear in mind that I am not a clinical researcher but represent the community of people living with a brain tumour. I realise that it would be impossible to state what impact COVID would have had on this research and although the period of interruption was only a very few weeks, but I wonder how the context of COVID would have impacted on patient and caregiver satisfaction with quality of life and treatment. I think this should be acknowledged in the limitations. Secondly, I feel that the research cited is missing some key evidence. You might want to explore here: https://brainstrust.org.uk/about-brainstrust/our-research/
I think too a comment about how burdensome patients and caregivers found completing the HRQoL questionnaires should be addressed, if they did find it burdensome.
Finally, I think too that COBRA should be referenced. This is work that has been done around Core Outcome Sets for Brain Cancer and is focused on people living with a GBM. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525958/
Author Response
Please see the attachment.
Author Response File: Author Response.pdf
